Skip to main content

Maze Therapeutics, Inc 8-K, filed Nov 9, 2026

Maze Therapeutics, Inc. (MAZE)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Maze Therapeutics, Inc filed this 8-K on November 9, 2026.

Maze Therapeutics completed HORIZON enrollment in more than 50 patients across three cohorts, expects final MZE829 data in early 2027, and reported $477.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits